I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
CMV Retinitis: Understanding and Protecting Your Vision
What Is CMV Retinitis
CMV retinitis is a progressive retinal infection caused by cytomegalovirus, a member of the herpesvirus family. Left untreated, it spreads across the retina and can destroy the tissue needed to see, resulting in permanent vision loss.
Cytomegalovirus is extremely widespread. Most healthy adults carry the virus in a dormant, or inactive, state without ever knowing it. The immune system, particularly a group of white blood cells called T-cells, keeps the virus suppressed under normal circumstances. When T-cell function drops severely, the virus can escape immune control and begin replicating in the retina.
Even after successful treatment, CMV remains in the body in a latent state within certain immune cells. This means the virus can reactivate if the immune system weakens again, which is why ongoing monitoring is so important for anyone who has had CMV retinitis.
CMV retinitis causes progressive areas of retinal necrosis, meaning retinal tissue dies as infected cells are destroyed. The infection spreads outward from its initial site, consuming healthy tissue as it advances. All layers of the retina can be affected, including the retinal pigment epithelium (RPE), a supportive layer just beneath the retina that is essential for maintaining photoreceptor cells.
The classic appearance during an eye examination is often described as a 'pizza pie' pattern, a combination of white, necrotic areas of retinal tissue mixed with patches of hemorrhage (bleeding). As photoreceptors are destroyed, vision loss occurs and cannot be reversed, which is why catching this infection early matters so much.
T-cells are the primary defenders that keep CMV in check. When the number or function of T-cells drops severely, whether from disease, medication, or other causes, CMV can break free and infect the retina.
The risk of CMV retinitis is highest when a specific type of T-cell, called a CD4+ T-cell, falls below 50 cells per microliter of blood. This threshold is an important marker that retina specialists and infectious disease physicians use to assess risk and guide monitoring decisions for their patients.
Who Is at Risk
CMV retinitis primarily affects people whose immune systems are severely impaired. Certain medical conditions and treatments that weaken immune defenses can place individuals at elevated risk, and knowing your personal risk is the first step toward appropriate screening and care.
Historically, CMV retinitis was most common among people with advanced AIDS. Before modern antiretroviral therapy became widely available, approximately 30 percent of people with AIDS developed CMV retinitis, according to the American Academy of Ophthalmology. The infection typically occurs when CD4+ T-cell counts fall below 50 cells per microliter and is rare when counts remain above 100 cells per microliter.
Those at highest risk include people not receiving antiretroviral treatment, those whose treatment has stopped working, and people with high levels of virus in their blood (called a high viral load) or a history of other opportunistic infections. An opportunistic infection is one that takes advantage of a weakened immune system that would otherwise keep it under control.
People who have received a solid organ transplant, such as a kidney, liver, or heart, take immunosuppressive medications to prevent the body from rejecting the new organ. These medications intentionally suppress the immune system, which can allow CMV to become active and spread to the retina.
The risk is particularly high in patients who had not previously been exposed to CMV but receive an organ from a donor who carries the virus. Transplant teams often prescribe antiviral medications as a precaution during the period of greatest immune suppression, but ongoing eye monitoring remains an important part of post-transplant care.
Several other medical situations can create conditions in which CMV retinitis may develop. These include people undergoing intensive chemotherapy, individuals taking high-dose immunosuppressive medications for autoimmune conditions, and those with certain immune deficiencies.
- Patients receiving chemotherapy for blood cancers or other malignancies
- People taking strong immunosuppressive medications for autoimmune diseases
- Newborns with congenital immune deficiencies
- Elderly individuals with significantly diminished immune function
It is also worth noting that strong local immunosuppression applied directly to the eye, such as sustained-release steroid implants, can occasionally create risk for CMV retinitis even when the rest of the immune system is functioning normally. Your retina specialist will consider all relevant factors when evaluating your individual risk.
Signs and Symptoms of CMV Retinitis
One of the most challenging aspects of CMV retinitis is that it can cause no symptoms at all in its early stages. By the time noticeable vision changes occur, significant damage may already have taken place. Knowing what to watch for, and acting quickly when symptoms appear, is critical to preserving vision.
Studies have found that roughly one-third of patients with CMV retinitis have no symptoms at the time of diagnosis, according to the American Academy of Ophthalmology. When early symptoms do occur, the most common complaint is new floaters, which are tiny spots, threads, or cobweb-like shapes that drift across the field of vision.
These floaters result from the inflammation and cellular debris the infection produces inside the eye. Any new or worsening floaters in a person with a weakened immune system should be evaluated promptly by a retina specialist, even if they seem minor or are not accompanied by other symptoms.
As CMV retinitis progresses, it can cause a shadow or dark area in the side, or peripheral, vision that gradually expands as more retinal tissue is damaged. Blurred or reduced vision is reported in nearly half of cases, according to the American Academy of Ophthalmology.
Additional symptoms that may develop include flashes of light, a veil or curtain effect across part of the visual field, and, if the infection reaches the macula, significant central vision loss. The macula is the small central region of the retina responsible for detailed, straight-ahead vision. Damage to the macula or optic nerve can result in permanent, irreversible vision impairment.
Some vision changes associated with CMV retinitis represent a medical emergency and require immediate attention. If you have a weakened immune system and experience any of the following, do not wait to be seen.
- A sudden increase in floaters or new floaters that appear rapidly
- Flashes of light, especially if new or worsening
- A shadow, dark area, or curtain spreading across your vision
- Sudden loss of vision in one eye
These symptoms may indicate rapidly advancing CMV retinitis or a related complication such as a retinal detachment. Contact a retina specialist or go to the nearest emergency room immediately. Early treatment can prevent permanent vision loss that might otherwise be avoided if care is delayed.
How CMV Retinitis Is Diagnosed
Diagnosis is primarily based on a thorough examination by a retina specialist. In most cases, the characteristic appearance of the retina provides enough information to confirm the infection. Additional testing may be used to assess the extent of damage or clarify the diagnosis in uncertain situations.
A dilated eye exam is the cornerstone of diagnosis. Dilating drops are placed in the eye to widen the pupil, allowing the retina specialist to examine the retina clearly using specialized lenses and instruments. The distinctive appearance of CMV retinitis, with whitish areas of necrotic tissue mixed with retinal hemorrhage, is usually recognizable enough to confirm the diagnosis during the examination itself.
The specialist will carefully map the location and extent of the infection during this exam. This baseline documentation is essential for tracking whether the disease is progressing or stabilizing and for evaluating the response to treatment over time.
Because CMV retinitis can cause no symptoms in its earliest stages, people at high risk should receive regular eye examinations even when they feel fine. Patients with HIV whose CD4+ T-cell counts fall below 50 cells per microliter should have eye examinations at least every three months, according to clinical guidelines.
For transplant recipients, screening frequency is guided by the degree of immune suppression and the patient's CMV exposure history. Early detection through routine screening gives treatment the best chance of preserving vision before significant damage has occurred.
In some cases, imaging and laboratory tests are used to supplement examination findings. Optical coherence tomography (OCT) creates detailed, cross-sectional images of the retina, helping the specialist assess the depth and extent of tissue involvement. Fundus photography captures high-resolution images of the retina for comparison over time. Wide-field imaging technology can document the full extent of disease across the retina, which is especially helpful when the infection has spread to the peripheral retina.
When the diagnosis is uncertain, a small sample of fluid from inside the eye can be tested for CMV genetic material using a technique called polymerase chain reaction, or PCR. This test can detect tiny amounts of the virus and help confirm CMV as the cause of the infection.
Treatment Options for CMV Retinitis
Treatment aims to stop the virus from spreading, preserve remaining vision, and prevent recurrence. The approach is individualized based on the location and severity of the infection, the patient's immune status, and their overall medical situation. A retina specialist works closely with the patient's infectious disease physician or transplant team throughout the entire process.
The primary treatment for CMV retinitis involves antiviral medications that target the virus throughout the body. Several medications are approved for this purpose, including ganciclovir (available in oral and intravenous forms), valganciclovir (taken by mouth), foscarnet, and cidofovir. Oral valganciclovir is now the most commonly used systemic treatment because of its convenience and reliable absorption.
Systemic treatment is often preferred because CMV can affect organs beyond the eyes, including the digestive tract and lungs. Addressing the virus body-wide helps reduce the risk of disease in other tissues. Treatment is typically divided into two phases: an induction phase lasting two to three weeks at higher doses, followed by a lower-dose maintenance phase to keep the infection suppressed.
In addition to systemic antiviral therapy, a retina specialist may also deliver medication directly into the eye through an intravitreal injection, an injection into the vitreous cavity, the gel-filled space inside the eye. Ganciclovir and foscarnet can both be administered this way, delivering a high concentration of the antiviral agent directly to the site of infection.
Intravitreal injections are especially valuable when the infection is located near the macula or optic nerve, where rapid progression could cause significant vision loss before oral medications reach full effect. This approach is often used alongside systemic therapy during the early, most critical period of treatment.
For people living with HIV, restoring immune function through highly active antiretroviral therapy (HAART) is the most important long-term strategy against CMV retinitis. According to the American Academy of Ophthalmology, HAART has reduced the overall incidence of CMV retinitis in people with HIV by 55 to 99 percent and has reduced the risk of disease progression by approximately 50 percent.
When CD4+ T-cell counts recover and remain consistently elevated, the risk of CMV reactivation decreases substantially. In some patients, maintenance antiviral therapy may be safely discontinued under close medical supervision once immune recovery is confirmed. Regular monitoring of both eye health and immune function remains essential even after therapy adjustments are made.
Research into new approaches for CMV retinitis is ongoing. One promising area involves adoptive cell transfer, a technique in which immune cells specifically trained to recognize and fight CMV are infused into the patient. Early studies of this immunotherapy approach have shown encouraging results, particularly for transplant recipients who must remain on long-term immunosuppressive medications and cannot rely on standard immune recovery to control the virus.
Our physicians are actively involved in clinical research and remain current with advances in retina care. While emerging therapies are not yet standard treatment, your retina specialist can discuss whether any investigational approaches may be appropriate for your individual situation.
What to Expect During and After Treatment
CMV retinitis requires sustained attention from a retina specialist and your broader medical team. Understanding what the treatment process involves, and what the long-term outlook may look like, helps patients prepare and stay engaged with their care.
During the induction phase, patients take higher doses of antiviral medication for approximately two to three weeks, or until the borders of the infection have stopped advancing. Eye examinations are performed frequently during this period to evaluate whether the retinitis is stabilizing. If intravitreal injections are part of the plan, patients may receive more than one injection during this initial phase.
Side effects from antiviral medications require monitoring and regular communication with your medical team. Ganciclovir and valganciclovir can reduce blood cell counts, making routine blood tests necessary. Foscarnet can affect kidney function and electrolyte levels in the blood. The retina specialist and the patient's primary care or infectious disease physician coordinate closely to watch for these effects and adjust treatment as needed.
The long-term prognosis for CMV retinitis has improved significantly with the availability of modern antiretroviral therapy. Before HAART, approximately one in three eyes with CMV retinitis progressed to retinal detachment, a serious complication in which the damaged retina separates from the underlying tissue. With HAART therapy, that rate has improved to roughly one in eight eyes, according to the American Academy of Ophthalmology.
It is important to understand that retinal tissue destroyed by CMV does not regenerate. Vision that is lost before treatment begins is typically not recoverable. Treatment works to preserve the remaining healthy retina and prevent further damage, but it cannot restore areas that have already been destroyed. This is why early detection and rapid treatment are so essential.
After the infection has stabilized, patients transition to a lower-dose maintenance regimen and continue with regular follow-up appointments to detect any sign of reactivation. For people with HIV who achieve strong immune recovery, maintenance antiviral therapy may eventually be tapered and stopped under careful supervision.
Even after maintenance therapy ends, periodic eye examinations remain important because the virus can reactivate if immune function declines again. The frequency of follow-up visits is tailored to each patient's individual circumstances and immune status, and our team will work with you to establish the right monitoring schedule.
Living With CMV Retinitis
Managing CMV retinitis extends beyond treating the retina itself. Immune health, quality of life, and emotional wellbeing all play important roles in the long-term picture, and our team is committed to supporting patients through every aspect of care.
For people with HIV, consistent adherence to antiretroviral therapy is the single most important factor in preventing CMV retinitis from returning or worsening. For transplant recipients, close collaboration with the transplant team is essential to find the right balance between preventing organ rejection and minimizing infection risk. Regular blood tests to monitor immune function help guide these decisions over time.
Some patients experience permanent changes in their vision, particularly if the macula or optic nerve was involved before treatment began. Low vision rehabilitation services can help patients make the most of their remaining vision through specialized training, magnification devices, and practical strategies for everyday activities.
Your retina specialist can refer you to appropriate low vision resources. Adjustments to home lighting, contrast, and daily routines can also meaningfully improve quality of life for people with lasting vision changes from CMV retinitis.
Living with a vision-threatening condition alongside an underlying immune disorder can be emotionally demanding. Counseling, peer support groups, and organizations dedicated to visual impairment or immune conditions can provide valuable connection and resources.
We are committed to treating the whole person, not just the retina. Our team can help connect you with support services tailored to your individual needs and circumstances.
Frequently Asked Questions
Patients and families often have practical questions about how CMV retinitis is managed day to day and what to expect over time. The answers below offer additional guidance and decision-making context beyond what is covered in the sections above.
Yes, reactivation is possible because cytomegalovirus remains latent in the body even after the retinitis resolves. This is the reason maintenance antiviral therapy is continued after the initial induction phase, and why stopping therapy is only done under careful medical supervision with close follow-up. If you notice any change in your vision while on or after maintenance therapy, contact your retina specialist promptly rather than waiting to see if symptoms resolve on their own.
The virus can be transmitted between people through contact with bodily fluids such as saliva, urine, blood, and breast milk, and most adults have been exposed to CMV at some point in their lives. CMV retinitis, however, is not something that passes directly from one person to another as an eye disease. The retinal infection develops only when a virus that is already dormant in the body reactivates in someone with a severely weakened immune system, not from eye-to-eye contact or casual exposure.
Treatment can stop the virus from spreading further and protect the retinal tissue that remains healthy, but retinal cells that have already been destroyed by the infection do not regenerate. The goal of treatment is to halt progression and preserve as much vision as possible, not to restore what has already been lost. How much vision can be maintained depends largely on how quickly treatment begins and how much of the retina was affected before the infection was controlled, which is why early diagnosis is so critical.
The induction phase typically lasts two to three weeks, after which most patients transition to a lower-dose maintenance regimen for as long as the immune system remains suppressed. For people with HIV who achieve robust immune recovery through antiretroviral therapy, it may eventually be possible to stop maintenance antiviral medication under close supervision. Patients who must remain on long-term immunosuppression, such as transplant recipients, may require antiviral therapy and careful monitoring for an extended or indefinite period. The exact duration is determined on an individual basis in consultation with your full medical team.
Yes, particularly if your CD4+ T-cell count is below 50 cells per microliter or you are in a period of high immune suppression following a transplant. Because a significant proportion of patients have no symptoms at the time of diagnosis, waiting for vision changes to appear means the infection may have already caused substantial, irreversible damage. Talk to your infectious disease physician or transplant team about when to schedule your first retinal examination so screening can begin at the right time.
Yes. As the infection destroys retinal tissue, the affected areas become thin and fragile, which increases the risk of a retinal detachment, a condition in which the retina separates from the back wall of the eye. Retinal detachment is a serious complication that requires urgent surgical repair and can cause severe vision loss if not addressed quickly. The risk of this complication has decreased substantially with modern antiretroviral therapy, but it remains a concern, especially when large areas of retinal tissue have been damaged before or during treatment.
Expert Retina Care When It Matters Most
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons bring deep expertise to the diagnosis and treatment of complex retinal infections, including CMV retinitis, with offices conveniently located across Connecticut. We understand that a diagnosis like this can feel overwhelming, and we are here to guide you through every step of your care with clarity, compassion, and individualized attention. Whether you have been referred by another physician or are seeking evaluation on your own, we welcome you to reach out and schedule an appointment at any of our four offices.
30 Years of Care & Commitment
